The invention concerns fluorescently labelled sulforaphane derivatives with strong and selective anticancer activity. These compounds combine the therapeutic properties of isothiocyanates with the ability to monitor their cellular behaviour through an integrated fluorophore.
The derivatives show higher anticancer potency than sulforaphane and act selectively on prostate and breast cancer cells while remaining non-toxic to healthy cells. Studies confirm rapid cellular uptake and predominant mitochondrial accumulation.
The fluorophore enhances anticancer activity and enables imaging of compound distribution as well as analysis of uptake and clearance dynamics.
The isothiocyanate group remains essential for activity, as demonstrated by inactive control derivatives lacking this motif.
The invention offers both a potential therapeutic molecule and a research tool for tracking cellular mechanisms of action.
Application:
- Development of selective next-generation anticancer therapeutics,
- Cellular imaging of sulforaphane derivative distribution and metabolism,
- Research on drug mechanisms and targeted therapy development.
